We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.44B
AUM Growth
-$537M
Cap. Flow
+$101M
Cap. Flow %
2.93%
Top 10 Hldgs %
35%
Holding
141
New
7
Increased
68
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$42.4M
2
PEN icon
Penumbra
PEN
+$31.3M
3
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$26.2M
4
HUM icon
Humana
HUM
+$25.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$94M
2
EHC icon
Encompass Health
EHC
+$35.7M
3
IRTC icon
iRhythm Holdings
IRTC
+$22M
4
XENT
Intersect ENT, Inc
XENT
+$15.4M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Consumer Staples 0.96%
3 Industrials 0.47%
4 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
76
Relay Therapeutics
RLAY
$4.37B
$10.4M 0.3%
618,267
+16,600
+3% +$356K
LUNG icon
77
Pulmonx
LUNG
$97.9M
$10.3M 0.3%
702,400
– –
IMTX icon
78
Immatics
IMTX
$1.33B
$9.82M 0.29%
+1,127,970
New +$8.92M
OHPAU
79
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$9.81M 0.29%
1,000,000
– –
AMYT
80
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$9.18M 0.27%
1,312,625
+6,800
+0.5% +$53K
CLDX icon
81
Celldex Therapeutics
CLDX
$3.37B
$9.04M 0.26%
335,477
+238,160
+245% +$6.92M
KDNY
82
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.88M 0.26%
507,512
-192,837
-28% -$3.03M
NVTA
83
DELISTED
Invitae Corporation
NVTA
$8.53M 0.25%
3,494,721
+170,900
+5% +$756K
AUPH icon
84
Aurinia Pharmaceuticals
AUPH
$2.06B
$8.19M 0.24%
815,126
+44,108
+6% +$493K
GH icon
85
Guardant Health
GH
$22.4B
$8.07M 0.23%
200,000
– –
KNTE
86
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$7.8M 0.23%
618,384
+274,238
+80% +$2.55M
VERV
87
DELISTED
Verve Therapeutics
VERV
$7.7M 0.22%
504,037
– –
NKTX icon
88
Nkarta
NKTX
$176M
$7.59M 0.22%
616,277
+106,329
+21% +$1.4M
MREO
89
Mereo BioPharma
MREO
$43.5M
$6.98M 0.2%
6,230,275
+155,332
+3% +$120K
DSGN icon
90
Design Therapeutics
DSGN
$897M
$6.45M 0.19%
460,391
+114,794
+33% +$1.55M
AKRO
91
DELISTED
Akero Therapeutics
AKRO
$6.42M 0.19%
679,514
+44,300
+7% +$462K
FOCL
92
EDAP TMS S.A.
FOCL
$228M
$6.19M 0.18%
910,000
+90,000
+11% +$624K
RYTM icon
93
Rhythm Pharmaceuticals
RYTM
$7.95B
$5.82M 0.17%
1,403,298
+166,272
+13% +$910K
FSTX
94
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.71M 0.14%
751,889
– –
EQRX
95
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.69M 0.14%
1,000,000
– –
ICVX
96
DELISTED
Icosavax, Inc. Common Stock
ICVX
$4.36M 0.13%
761,557
– –
BEAM icon
97
Beam Therapeutics
BEAM
$2.82B
$4.31M 0.13%
+111,430
New +$4.43M
CYPH
98
Cypherpunk Technologies Inc
CYPH
$72.4M
$4.2M 0.12%
365,295
+5,750
+2% +$74.4K
ADAP
99
DELISTED
Adaptimmune Therapeutics
ADAP
$4.01M 0.12%
2,357,544
+60,350
+3% +$104K
XLO icon
100
Xilio Therapeutics
XLO
$60.5M
$3.98M 0.12%
97,348
+12,270
+14% +$649K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rock Springs Capital Management held 141 positions worth $3.44B, down 14% from $3.97B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q2 2022 filing shows 7 new, 68 increased, 12 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 200,000 shares worth $25.6M. The largest sale was HCA Healthcare, an estimated $94M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q2 2022 buy was State Street Health Care Select Sector SPDR ETF: 200,000 shares worth $25.6M.
  • Rock Springs Capital Management added most to Align Technology in Q2 2022, an estimated $42.4M increase.
  • Rock Springs Capital Management's biggest Q2 2022 reduction was iRhythm Holdings, cutting an estimated $22M.
  • Rock Springs Capital Management fully exited HCA Healthcare in Q2 2022, selling an estimated $94M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.44B portfolio in Q2 2022.
  • Rock Springs Capital Management opened 7 new positions and closed 10 in Q2 2022.
  • Rock Springs Capital Management's portfolio value fell 14% quarter-over-quarter to $3.44B.

Based on Rock Springs Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.